Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases.
Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, Kingsmore SF. · 2018
Read Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. by Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, Kingsmore SF. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6037748.txt.
Introduction
Clark and co-authors compare genetic tests for sick children. Their meta-analysis appeared in NPJ Genomic Medicine. Genetic diseases are a leading cause of childhood death. Finding the cause fast can change care decisions. Three test types compete for first-line use.
The review covered 37 studies with 20,068 children. Genome sequencing found a cause in 41 percent. Exome sequencing reached 36 percent. Chromosomal microarray reached only 10 percent. Sequencing also changed care more often than microarray. Testing parent-child trios beat testing children alone. Hospital-based reading outperformed reference labs in the data. The authors back sequencing as a first-line test. Readers get pooled numbers to guide testing choices.
Catalog record
| CREATOR | Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, Kingsmore SF. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases By Michelle M. Clark, Zornitza Stark, Lauge Farnaes, Tiong Y. Tan, Susan M. White, David Dimmock, Stephen F. Kingsmore Published in: NPJ Genomic Medicine DOI: 10.1038/s41525-018-0053-8 ABSTRACT Genetic diseases are leading causes of childhood mortality. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are relatively new methods for diagnosing genetic diseases, whereas chromosomal microarray (CMA) is well established. Here we compared the diagnostic utility (rate of causative, pathogenic, or likely pathogenic genotypes in known disease genes) and clinical utility (proportion in whom medical or surgical management was changed by diagnosis) of WGS, WES, and CMA in children with suspected genetic diseases by systematic review of the literature (January 2011–August 2017) and meta-analysis, following MOOSE/PRISMA guidelines. In 37 studies, comprising 20,068 children, diagnostic utility of WGS (0.41, 95% CI 0.34–0.48, I2 = 44%) and WES (0.36, 95% CI 0.33–0.40, I2 = 83%) were qualitatively greater than CMA (0.10, 95% CI 0.08–0.12, I2 = 81%). Among studies published in 2017, the diagnostic utility of WGS was significantly greater than CMA (P < 0.0001, I2 = 13% and I2 = 40%, respectively). Among studies featuring within-cohort comparisons, the diagnostic utility of WES was significantly greater than CMA (P < 0.001, I2 = 36%). The diagnostic utility of WGS and WES were not significantly different. In studies featuring within-cohort comparisons of WGS/WES, the likelihood of diagnosis was significantly greater for trios than singletons (odds ratio 2.04, 95% CI 1.62–2.56, I2 = 12%; P < 0.0001). Diagnostic utility of WGS/WES with hospital-based interpretation (0.42, 95% CI 0.38–0.45, I2 = 48%) was qualitatively higher than that of reference laboratories (0.29, 95% CI 0.27–0.31, I2 = 49%); this difference was significant among studies published in 2017 (P < .0001, I2 = 22% and I2 = 26%, respectively). The clinical utility of WGS (0.27, 95% CI 0.17–0.40, I2 = 54%) and WES (0.17, 95% CI 0.12–0.24, I2 = 76%) were higher than CMA (0.06, 95% CI 0.05–0.07, I2 = 42%); this difference was significant for WGS vs CMA (P < 0.0001). In conclusion, in children with suspected genetic diseases, the diagnostic and clinical utility of WGS/WES were greater than CMA. Subgroups with higher WGS/WES diagnostic utility were trios and those receiving hospital-based interpretation. WGS/WES should be considered a first-line genomic test for children with suspected genetic diseases. INTRODUCTION Genetic diseases (single-gene disorders, genomic structural defects, and copy number variants) are a leading cause of death in children less than ten years of age.1–8 Establishing an etiologic diagnosis in children with suspected genetic diseases is important for timely implementation of precision medicine and optimal outcomes, particularly to guide weighty clinical decisions such as surgeries, extracorporeal membrane oxygenation, therapeutic selection, and palliative care.9 With the exception of a few genetic diseases with pathognomonic findings at birth, such as chromosomal aneuploidies, etiologic diagnosis requires identification of the causative molecular basis. In practice, this is remarkably difficult for several reasons: firstly, genetic heterogeneity—there are over 5200 genetic disorders for which the molecular basis has been established.10 Secondly, clinical heterogeneity—genetic disease presentations in infants are frequently formes frustes of classic descriptions in older children (see, for example Inoue et al.11). Thirdly, comorbidity is frequent in infants with genetic diseases—including prematurity, birth trauma, and sepsis—obfuscating clinical presentations.2 Fourthly, approximately four percent of children have more than one genetic diagnosis.12 Finally, disease progression is faster in children, switching the diagnostic odyssey to a race against time.9,13,14 Traditionally, establishment of molecular diagnoses was by serial testing guided by the differential diagnosis. CMA is the recommended first-line genomic test for children with several types of genetic diseases.15,16 Serial testing employs many other tests—including newborn screening panels, metabolic testing, cytogenetics, chromosomal fluorescence in situ hybridization, single-gene sequencing, and sequencing of panels of genes associated with specific disease types (such as sensorineural deafness, cardiac dysrhythmias, or epilepsy).15 Iterative inquiry of differential diagnoses, however, frequently incurs a diagnostic odyssey and rarely allows etiologic diagnosis in time to influence acute management. Thus, inpatient management of children with suspected genetic diseases largely remains empiric, based on clinical diagnoses.9 Over the past five years, WGS and WES have started to gain broad use for etiologic diagnosis of infants and children with suspected genetic diseases.17–48 By allowing concomitant examination of all or most genes in the differential diagnosis, WGS and WES have the potential to permit comprehensive and timely ascertainment of genetic diseases. Timely molecular diagnosis, in turn, has the potential to institute a new era of precision medicine for genetic diseases in children. During this period, WGS and WES methods have improved substantially. While numerous studies have been published,17–48 there are not yet guidelines for their use by clinicians. Here we report a literature review and meta-analysis of the diagnostic and clinical utility of WGS and WES, compared with CMA, in children (age 0–18 years) with any suspected genetic disease. RESULTS WGS and WES are relatively new methods for diagnosis of childhood genetic diseases. We compared the diagnostic utility of WGS and WES with that of CMA, the recommended first-line genomic test for genetic diseases in children with intellectual disability, developmental delay, autism spectrum disorder, and multiple congenital anomalies.15,16 A total of 2093 records were identified by searches for studies of the diagnostic utility of WGS, WES, and CMA in affected children with a broad range of suspected genetic diseases (Figure S1). Thirty seven of these, featuring 20,068 children, met eligibility criteria and were included in qualitative analyses (Tables 1 and 2).17–54 Thirty-six were case studies; one was a randomized controlled trial.26 In these, the pooled diagnostic utility of WGS was 0.41 (95% CI 0.34–0.48, seven studies, 374 children, I2 = 44%), which was qualitatively greater than WES (0.36, 95% CI 0.33–0.40, 26 studies, n = 9014, I2 = 83%) or CMA (0.10, 95% CI 0.08–0.12, 13 studies, n = 11,429, I2 = 81%, Fig. 1a). Severe heterogeneity (I2 > 75%) within the WES and CMA groups precluded statistical comparisons.Table 1Characteristics of studies reporting diagnostic or clinical utility of WES or WGSCitationSiteNumber of proband childrenGenetic diseases testedProband age (mean or median)Reference Lab Or Hospital Or Research TestWES or WGSSingleton or TrioConsanguinityaMolecular diagnosis rateDe novo variant diagnosis rateRate of clinical utilitybZhu et al.17US119Any9.5 yrResearchWEST8%24%45%n.d.Lee et al.18US520Any<18 yrRefLabWESBothc6%26%50%n.d.Yang et al.19US1745Any6 yrRefLabWESSn.d.26%47%n.d.Yang et al.20US218Any<18 yrReflabWESSn.d.27%47%n.d.Sawyer et al.21CA362AnyallResearchWESBothc21%29%n.d.6%Retterer et al.22US3040Any7 yrRefLabWESBothcn.d.29%43%n.d.Vissers et al.23NL150Neuro5 yr 7 moRefLabWEST5%29%70%n.d.Taylor et al.d24UK68Anyn.d.ResearchWESBoth17%29%n.d.n.d.Trujillano et al.25Mixed820Any<15 yrRefLabWEST45%30%24%n.d.Petrikin et al.26US37Any<4 moHWGST3%30%61%41%Valencia et al.27US40Any7 yrHWESTn.d.30%33%18%Farwell et al.28US417Any<18 yrRefLabWESBothcn.d.31%49%n.d.DDD29,30UK1133NDD5.5 yrResearchWEST3%31%64%n.d.Iglesias et al.31US91Any<18 yrHWESS11%32%41%18%Thevenon et al.32FR43Neuro<18 yrHWESSn.d.33%n.d.9%Meng et al.33US178Any28 daysHWESSn.d.33%n.d.n.d.Taylor et al.d24UK68Anyn.d.ResearchWGSBoth17%34%18%n.d.Stavropoulos et al.34CA100Any5.5 yrHWGSS8%34%57%n.d.Bick et al.35US22Any<18 yrHWGSSn.d.36%n.d.27%Lionel et al.36CA70Any<18 yrHWESS9%37%n.d.n.d.Soden et al.e37US85NDD7 yrHWEST5%40%50%21%Farnaes et al.38US42Any<1 yrHWGST2%40%38%31%Srivastava et al.39US78NDD9 yrHWESS4%41%56%27%Baldridge et al.40US155Any6 yrRefLab + HWESS4%43%38%5%Meng et al.33US100Any28 daysHWESTn.d.44%n.d.19%Monies et al.41SA270Any<18 yrHWESS49%45%22%n.d.Eldomery et al.f42US63Any<18 yrResearchWESTn.d.48%n.d.n.d.Kuperberg et al.43IS57Neuro<18 yrHWESSn.d.49%61%9%Lionel et al.36CA70Any<18 yrHWGST9%50%n.d.n.d.Tan et al.44AU44Any2–18 yrHWESSn.d.52%61%14%Charng et al.45SA31NDDallResearchWESBoth90%55%24%n.d.Willig et al.46US35Any26 daysHWGST3%57%65%37%Stark et al.47AU80Any8 moHWESS21%58%35%23%Tarailo-Graovac et al.48CA41Any6 yrResearchWEST15%68%39%44%Sum/Average 28 10392 17% 31% 44% 18% Range 22-3040 2–90% 24–68% 18–70% 5–44% AU Australia, CA Canada, IS Israel, NDD neurodevelopmental disabilities, Neuro neurologic, NL Holland, SA Saudi Arabia, UK United KingdomThe statistics in bold are calculated across all rows.aBy history or based on long runs of homozygositybOther than reproductive planscStatistical difference between S and T within studydBespoke methods for de novo variantseCorrected to